Printer Friendly

DEPRENYL RESEARCH LIMITED ANNOUNCES ELDEPRYL(R) LISTED ON THE ONTARIO DRUG BENEFIT FORMULARY

 TORONTO, Dec. 16 /PRNewswire/ -- Deprenyl Research Limited (TSE: DEP; NASDAQ: DEPLF) today announced that it has been informed by the Ontario Ministry of Health that Eldepryl(R) has been added to the Ontario Drug Benefit Formulary. As of Jan. 1, 1993 all Eldepryl(R) prescriptions will be paid in full by the Ontario Drug Benefit Plan for all Ontario residents over 65 and younger patients who are recipients of social assistance. The Drug Quality and Therapeutics Committee which is the most senior advisory body to the Ontario Ministry of Health on the efficacy and appropriateness of drugs, accepted the new Eldepryl(R) indication for early use in Parkinson's disease and recommended that Eldepryl(R) be added to the Ontario Drug Benefit Formulary "in the interest of Ontario patients with Parkinson's." Eldepryl(R) was previously available without charge to patients with advanced Parkinson's in limited
circumstances and after special certification by a physician. Deprenyl believes that this development is particularly encouraging for sales of Eldepryl(R), as Ontario represents its largest provincial market.
 Deprenyl Research Limited is a Canadian pharmaceutical company with several development stage affiliates. It develops and markets pharmaceutical agents for neurologic diseases, chronic diseases and diseases of aging and dermatology.
 -0- 12/16/92
 /CONTACT: Martin Barkin, M.D., president and CEO; or Deborah Worobec, investor relations, 416-537-4372, both of Deprenyl Research Limited; or Jim Tolan, senior vice president, O'Connor Biro and Associates, 708-498-2284, for Deprenyl Research Limited/
 (DEPLF)


CO: Deprenyl Research Limited ST: Ontario IN: MTC SU:

LR -- NY012 -- 7560 12/16/92 08:53 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 16, 1992
Words:259
Previous Article:SAFECARD WYOMING RELOCATION COMPLETE, FOURTH QUARTER EARNINGS CHARGE, DIVIDEND CHANGE; PETER HALMOS NO LONGER WITH THE COMPANY
Next Article:SURVEY FINDS PUBLIC SUPPORT FOR CHANGES IN AUTO INSURANCE SYSTEM
Topics:


Related Articles
DEPRENYL RESEARCH CO-CHAIRMAN SENDS LETTER TO SHAREHOLDERS
DEPRENYL ADJOURNS APPLICATION FOR INJUNCTION
DEPRENYL RESEARCH COMMENTS ON NEWSPAPER REPORT
DEPRENYL RESEARCH LIMITED REPORTS EARNINGS
DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
DEPRENYL RESEARCH LIMITED ANNOUNCES FOURTH QUARTER RESULTS TO BE RELEASED MID-FEBRUARY
INTRODUCTION OF GENERIC PARKINSON DRUG TO HELP PATIENTS AND PROVINCIAL GOVERNMENTS
DEPRENYL RESEARCH LIMITED AND NOVOPHARM LIMITED ANNOUNCE STRATEGIC ALLIANCE
DEPRENYL RESEARCH TAKES NEW NAME: DRAXIS HEALTH INC.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters